To the Editor: Contrary to early expectations, the co-occurrence of leprosy and HIV has not increased globally (1) . However, most of the larger studies on the subject were conducted in the early to mid-1990s in African countries, and the research designs had limited power to describe the true effects of co-infection (1) . Moreover, the introduction of highly active antiretroviral therapy (HAART), which has been used routinely in Brazil since 1996, altered the clinical evolution of HIV infection (2) and led to increasing reports of immune restoration infl ammatory syndrome (IRIS) associated with leprosy (3, 4) . Although some researchers have argued that this association may not affect public health (2), its true importance remains to be clarifi ed. Finally, leprosy has a wide range of clinical manifestations, which sometimes imposes a clinical challenge and may lead to misdiagnosis (5) . Together, these factors may have helped mask the true scenario of leprosy and HIV co-infection, particularly in areas where these conditions are highly endemic. In this context, case reports from referral centers that refl ect the broad clinical aspects of leprosy and HIV co-occurrence are important to increase clinicians' awareness of both diseases.
We report 3 HIV-positive/AIDS patients who showed different clinical manifestations of leprosy; their conditions were diagnosed before and after HAART initiation. All patients lived in Manaus, the capital of the state of Amazonas in Brazil, an area where both leprosy and HIV infection are endemic. The 3 patients represent a sample from our 11-year experience (Figure) . There was decreased pain sensitivity in the lesion and no nerve enlargement. At that time, her CD4 cell count was 372 cells/μL. Histopathologic examination showed tuberculoid granulomas consisting of lymphocytes and epithelioid cells. Wade staining showed no acidfast bacilli. Histopathologic fi ndings led to a diagnosis of BT leprosy. MDT for paucibacillary leprosy was promptly started, and HAART was continued. When she was last seen, in December 2008, the skin lesion had disappeared and she was still receiving MDT.
The reliability of the cardinal signs of leprosy (hypopigmented or reddish patches with defi nite loss of sensation, thickened peripheral nerves, and positive skin smears or biopsy material) has been widely accepted (5). However, in some diffi cult cases, the defi nitive diagnosis relies solely on the histopathologic examination, which often depends on the experience of the pathologists working in referral centers. According to most pre-HAART studies, the clinical spectrum of leprosy seems to be preserved in HIV-positive and AIDS patients (1) . This is in agreement with the course of disease in patient 1 (a typical BT lesion before initiating HAART) and patient 2 (a typical multibacillary leprosy in a full-blown AIDS background). For patient 3, a distinct outcome was observed: the appearance of an atypical BT lesion during HAART. Recently, we reported 3 cases of IRIS associated with leprosy in which BL leprosy shifted unexpectedly to BT leprosy (4, 6) . Host genetic make-up and unknown consequences of HIV-infection over specifi c leprosy immune mechanism may be implicated in these unusual outcomes. Further prospective studies should be performed to elucidate these fi ndings.
Although previous studies have shown that HIV infection is not a risk factor for leprosy (1), clinicians should be aware of this potential co-infection, which may mimic different skin diseases. Moreover, reports of leprosy after HAART initiation have been described from countries where leprosy is not endemic (7) . Precise diagnosis and prompt treatment of leprosy in coinfected persons are mandatory. 
